Dual diagnosis in Depression: Treatment recommendations

Judit Tirado-Muñoz, Adriana Farré, Joan Mestre-Pintó, Nestor Szerman, Marta Torrens

Research output: Contribution to journalReview articleResearchpeer-review

33 Citations (Scopus)


© 2018, Edita Socidrogalcohol. All rights reserved. Comorbidity between substance use disorders (SUD) and major depression (MD) is the most common dual pathology in the field of addiction to substances and has prevalence rates ranging between 12% and 80%, which complicates the response to treatment and worsens the prognosis of patients. Differentiating between diagnoses of induced depressive episodes and primary depressive episodes concurrent to substance use is especially relevant for therapeutic management. This article presents the state of the art of the currently available pharmacologic treatments of comorbid depression in patients with SUD, taking into account the safety and risk of abuse of antidepressant drugs. Due to the fact that comorbidity of MD and SUD is frequent and presents greater psychopathological and medical severity, as well as worse social functioning, it is crucial to treat MD and SUD simultaneously using the integrated treatment model and not to treat both conditions separately.
Original languageEnglish
Pages (from-to)66-76
Issue number1
Publication statusPublished - 1 Jan 2018


  • Comorbidity
  • Depression
  • Dual pathology
  • Recommendations
  • Treatment


Dive into the research topics of 'Dual diagnosis in Depression: Treatment recommendations'. Together they form a unique fingerprint.

Cite this